Skip to main content
Study links better glycemic control with semaglutide use in diabetes

UK researchers evaluated 632 type 2 diabetes patients with insufficient glycemic control and found that those who received oral semaglutide had significant reductions in mean change in A1C level from baseline to week 26, compared with those on placebo. The findings were published in the Journal of the American Medical Association.

Full Story: